Select Topic
Bispecific T-cell engager (BiTE) therapy is an advanced form of immunotherapy designed to bring T-cells directly into contact with cancer cells. By linking the body’s immune cells to tumor cells, it helps T-cells recognize and destroy cancer more effectively. This therapy is used in the treatment of lung cancer, melanoma, and certain types of blood cancers.
BiTEs are engineered antibodies with two distinct binding sites:
By physically linking T cells to cancer cells, BiTEs enable direct immune-mediated destruction of malignant cells.
Once administered, BiTE therapy works through the following steps:
BiTE therapy relies on specially engineered antibodies designed to bind to two different targets at once. Antibodies normally protect the body by identifying unfamiliar or harmful proteins. In this therapy, one part of the antibody attaches to a T-cell, while the other binds to a cancer cell—effectively bringing the two together.
A key advantage of this mechanism is that T-cell activation does not rely on conventional antigen presentation, allowing BiTEs to overcome certain immune evasion mechanisms of cancer.
Compared with traditional treatment modalities, BiTE therapy offers several unique advantages:
During BiTE therapy, the medication is given either as an injection or through an intravenous (IV) infusion. Treatment typically begins with a low dose, which is gradually increased over several days. This step-by-step approach allows your healthcare team to safely reach the dose that is most appropriate for your individual condition.
BiTE therapy has been successfully used and actively studied in several cancer types, particularly:
Patient selection depends on tumor characteristics, antigen expression, and overall clinical condition.
As with other immunotherapies, BiTE treatment may be associated with immune-related adverse events, including:
Therefore, BiTE therapy should be delivered in specialized medical centers with:
When standard treatment options are no longer effective, BiTE therapy may be considered for patients with the following conditions:
The successful delivery of BiTE therapy requires a high level of institutional preparedness. At Vejthani Life Cancer Center, this readiness is supported by a comprehensive, patient-centered ecosystem that includes:
Together, these capabilities ensure that every patient receives safe, effective, and personalized cancer care, delivered to global standards, reflecting Vejthani’s objective to advanced treatment.
Cancer Center, Vejthani International Hospital
Call: (+66)2-734-0000 Ext. 2720, 2721
English Hotline: (+66)85-223-8888
